- Residency - Columbia University Medical Center (1965-1968), Neurology
- Internship - Harvard Medical School/Beth Israel Deaconess Medical Center (1964-1965), Internal Medicine
- Medical School - Northwestern University Medical School
Roger Rosenberg, M.D.
- The Abe (Brunky), Morris and William Zale Distinguished Chair in Neurology
- Memory Disorders
Development of a DNA Aβ42 Vaccine to Prevent Alzheimer’s Disease is my major scientific interest and effort in my laboratory. I have spent the past 30 years in research in neurodegenerative diseases and Alzheimer’s disease in particular. I have been at the University of Texas Southwestern Medical Center since 1973, hold the Abe (Brunky), Morris and William Zale Distinguished Chair, am Professor of Neurology and Physiology and have Chaired the Department of Neurology from 1973- 1991. I am the founding Director of the NIH funded Alzheimer’s Disease Center at UT Southwestern and it has been funded now through five consecutive competitive funding cycles since 1988 and will be funded through 2016 representing 28 years of continuous NIH Center funding.
My early amyloid related research in the UT Southwestern Alzheimer’s Disease Center is directed at determining amyloid precursor protein (APP) processing by neural cells in culture as a model system for the abnormal deposition of amyloid in the brain of Alzheimer’s disease patients. I have described a platelet APP bio-marker that correlates in a linear manner with the severity of patient dementia . In 2006, I published that human platelets utilize beta and gamma secretase to produce Aβ42 and that platelets from Alzheimer’s disease patients synthesize more Aβ42 than control platelets due to an increased activity of beta-secretase. Platelet A β42 levels may be an important bio-marker for Alzheimer’s disease and a means to monitor effectiveness of drug effect in clinical trials.
In 2006, I published with colleagues in my laboratory that a DNA A β42 vaccine can reduce Abeta42 peptide levels in the brain of AD transgenic mice by 50%. Since 2003, we have shown a DNA A β42 vaccine with the gene gun produces in Alzheimer transgenic mice an anti-A β42 antibody of the IgG1/Th2 type which is known to be anti-inflammatory. More recently we have shown that this DNA vaccine induces CD4 non-inflammatory spleenocytes and not CD8 pro-inflammatory cells which are induced by Aβ42 peptide vaccination. We have shown that A β42 peptide vaccination produces a Th1 and Th2 immune response that is 1:1( IgG1 ratio with IgG2a is 1:1) and thus brain inflammation with A β42 peptide vaccination is due to the induction of a pro-inflammatory immune response not seen with DNA A β42 vaccination. The DNA vaccine produces a highly predominant Th2 immune response (Th2/Th1 is 10:1 ratio). A clinical trial with Alzheimer’s disease patients is being developed using this new DNA gene vaccination methodology. I received in 2009 a US Patent as the Inventor of “Amyloid Beta Gene Vaccines”.
My other major area of research has been the molecular and clinical study of genetic neurological diseases. In that regard, I have been most active in studying the inherited ataxias including Machado-Joseph disease which I described initially with William Nyhan, M.D. Ph.D, in 1976. Our collaborative group mapped the chromosomal location of this disease to 14q24.3, and determined the molecular mutation causal of the disease in patients throughout the world (United States, Portugal, Canada, Japan, Brazil, Spain, France, England, China) is an increase in CAG unstable DNA triplet repeats which represents a novel, new mechanism of disease. CAG repeat levels in the MJD gene is now a commercially available bio-marker which has been shown to be effective in reducing the prevalence of this dominantly inherited spinocerebellar degeneration in at risk persons in families known to have the disease.
- Texas Neurological Society
- Society for Neuroscience
- American Neurological Association
- American Academy of Neurology
- World Federation of Neurology Trustee 2009, 2005-2009
- Honorary Member (Elected) 2006, American Neurological Association
- Nancy R. McCune Research Award 2005, Alzheimer’s Association (AWARE)
- American Medical Association 1997, Editor in Chief, Archives of Neurology (1997-present); Editorial Board JAMA (1997-present)
- 1st Distinguished Neurology Alumnus Award of the Neurological Institute; Columbia University Medical Center 1994
- Elected Honorary Member, Spanish Neurological Society 1994
- American Academy of Neurology 1991, President
- World Federation of Neurology 2009, 1st Science Medal for Scientific Achievements in Neurology and Neuroscience; presented at the World Congress of Neurology in Bangkok, Thailand.
- University of Texas Chancellor's Council Lecture, Presented "DNA Abeta42 Vaccination to Prevent Alzheimer's Disease" May 2013, Austin, Texas
- Chief Resident 1968, H. Houston Merritt Center for Neuromuscular and Mitochondrial Disorders
- Northwestern University Alumni Association Merit Award 1986
- American Neurological Association 1988, 1st Vice President
- American Association for the Advancement of Science 1991, Elected Fellow
Rosenberg's The Molecular and Genetic Basis of Neurologic and Psychiatric Disease
Roger N. Rosenberg, MD and Juan Pascual, MD (2014), Boston, Elsevier
- Rosenberg's The Molecular and Genetic Basis of Neurologic and Psychiatric Disease
Translational research in neurology and neuroscience 2010-2011.
Rosenberg RN Archives of neurology 2010 Oct 67 10 1176
Analysis of three plasmid systems for use in DNA A beta 42 immunization as therapy for Alzheimer's disease.
Qu BX, Lambracht-Washington D, Fu M, Eagar TN, Stüve O, Rosenberg RN Vaccine 2010 Jul 28 32 5280-7
Altered Amyloid Protein Processing in Alzheimer's Disease Patient Platelets
Rosenberg RN, Baskin F, Fosmire J, Risser R, et al. Archives of Neurology 1997 54 139-144
Abeta42 gene vaccination reduces brain amyloid plaque burden in transgenic mice
Qu B-X, Boyer PJ, Johnston SA, Hynan LS, Rosenberg RN J. Neurol. Sci. May 2006 244 151-158
Platelet amyloid precursor protein processing: a bio-marker for Alzheimer disease
Tang K, Hynan LS, Baskin F, and Rosenberg RN J. Neurol. Sci. Fall 2006 240 53-58
Mitochondrial Therapy for Parkinson Disease
Rosenberg RN Archives of Neurology 2002 59 1523
Evolutionary Time and Human Memory
Rosenberg RN JAMA 2002 288 3045-3047
Rosenberg RN Archives of Neurology 2001 58 1739-1741
Genomics and the Transformation of Neurology
Rosenberg RN JAMA 2001 286 2869-2870
Genetic Factors for the Development of Alzheimer's Disease in the Cherokee Indian
Rosenberg RN, Richter RW, Risser RC, et al. Archives of Neurology 1996 53 997-1000
Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes.
Jun G, Naj AC, Beecham GW, Wang LS, Buros J, Gallins PJ, Buxbaum JD, Ertekin-Taner N, Fallin MD, Friedland R, Inzelberg R, Kramer P, Rogaeva E, St George-Hyslop P, Cantwell LB, Dombroski BA, Saykin AJ, Reiman EM, Bennett DA, Morris JC, Lunetta KL, Martin ER, Montine TJ, Goate AM, Blacker D, Tsuang DW, Beekly D, Cupples LA, Hakonarson H, Kukull W, Foroud TM, Haines J, Mayeux R, Farrer LA, Pericak-Vance MA, Schellenberg GD Archives of neurology 2010 Dec 67 12 1473-84
DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model.
1. Lambracht-Washington D, Qu BX, Fu M, Eagar TN, Stuve O, Rosenberg RN. 2009 Oct 28 302(16):1796-802
DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model.
Lambracht-Washington D, Qu BX, Fu M, Eagar TN, Stüve O, Rosenberg RN JAMA : the journal of the American Medical Association 2009 Oct 302 16 1796-802
The relationship of cardiovascular risk factors to Alzheimer disease in Choctaw Indians.
Weiner MF, Hynan LS, Rossetti H, Womack KB, Rosenberg RN, Gong YH, Qu BX The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2011 May 19 5 423-9
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.
Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, Larson EB, Bird TD, Boeve BF, Graff-Radford NR, De Jager PL, Evans D, Schneider JA, Carrasquillo MM, Ertekin-Taner N, Younkin SG, Cruchaga C, Kauwe JS, Nowotny P, Kramer P, Hardy J, Huentelman MJ, Myers AJ, Barmada MM, Demirci FY, Baldwin CT, Green RC, Rogaeva E, St George-Hyslop P, Arnold SE, Barber R, Beach T, Bigio EH, Bowen JD, Boxer A, Burke JR, Cairns NJ, Carlson CS, Carney RM, Carroll SL, Chui HC, Clark DG, Corneveaux J, Cotman CW, Cummings JL, DeCarli C, DeKosky ST, Diaz-Arrastia R, Dick M, Dickson DW, Ellis WG, Faber KM, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Gilman S, Giordani B, Glass JD, Growdon JH, Hamilton RL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT, Jicha GA, Jin LW, Johnson N, Karlawish J, Karydas A, Kaye JA, Kim R, Koo EH, Kowall NW, Lah JJ, Levey AI, Lieberman AP, Lopez OL, Mack WJ, Marson DC, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Parisi JE, Perl DP, Peskind E, Petersen RC, Poon WW, Quinn JF, Rajbhandary RA, Raskind M, Reisberg B, Ringman JM, Roberson ED, Rosenberg RN, Sano M, Schneider LS, Seeley W, Shelanski ML, Slifer MA, Smith CD, Sonnen JA, Spina S, Stern RA, Tanzi RE, Trojanowski JQ, Troncoso JC, Van Deerlin VM, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Williamson J, Woltjer RL, Cantwell LB, Dombroski BA, Beekly D, Lunetta KL, Martin ER, Kamboh MI, Saykin AJ, Reiman EM, Bennett DA, Morris JC, Montine TJ, Goate AM, Blacker D, Tsuang DW, Hakonarson H, Kukull WA, Foroud TM, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD Nature genetics 2011 May 43 5 436-41
DNA Immunization Against Amyloid beta 42 has High Potential as Safe Therapy for Alzheimer's Disease as it Diminishes Antigen-Specific Th1 and Th17 Cell Proliferation.
Lambracht-Washington D, Qu BX, Fu M, Anderson LD, Stüve O, Eagar TN, Rosenberg RN Cellular and molecular neurobiology 2011 Aug 31 6 867-74
Brain MRI, apoliprotein E genotype, and plasma homocysteine in American Indian Alzheimer disease patients and Indian controls.
Weiner MF, de la Plata CM, Fields BA, Womack KB, Rosenberg RN, Gong YH, Qu BX, Diaz-Arrastia R, Hynan LS Current Alzheimer research 2009 Feb 6 1 52-8
Intradermal active full-length DNA Aß42 immunization via electroporation leads to high anti-Aß antibody levels in wild-type mice.
Rosenberg RN, Fu M, Lambracht-Washington D Journal of neuroimmunology 2018 Jun
immunization in 3xTg-AD mice reduces not only amyloid deposition but also tau pathology.
Rosenberg RN, Fu M, Lambracht-Washington D Alzheimer's research & therapy 2018 Nov 10 1 115
Genomics of Alzheimer Disease: A Review.
Rosenberg RN, Lambracht-Washington D, Yu G, Xia W JAMA neurology 2016 May
Active Immunotherapy to Prevent Alzheimer Disease-A DNA Amyloid ß 1-42 Trimer Vaccine.
Rosenberg RN, Lambracht-Washington D, JAMA neurology 2019 Dec
Evaluation of a DNA Aß42 vaccine in adult rhesus monkeys (Macaca mulatta): antibody kinetics and immune profile after intradermal immunization with full-length DNA Aß42 trimer.
Lambracht-Washington D, Fu M, Frost P, Rosenberg RN Alzheimer's research & therapy 2017 Apr 9 1 30
- Translational research in neurology and neuroscience 2010-2011.
- Neurodegenerative Disorders
- Clinical and Molecular Neurogenetics; genomics
- Alzheimer's Disease
- Memory Disorders